Crown Reserve Acquisition Corp. I amended its Carvix Business combination agreement on August 26, 2026, clarifying exactly which Shareholder votes need simple-majority versus two-thirds approval. Voting rights themselves are unchanged, giving investors a clearer roadmap for how the pending Carvix Merger will be approved.
Key Highlights
- Annex A to the amendment locks in minimum annualized base salaries for named Carvix executives, tied to satisfying a condition under the Carvix disclosure schedule.
- Crown Reserve Acquisition Corp. I revised voting mechanics for its merger with Carvix, Inc. on August 26, 2026, without changing shareholders' actual voting rights.
- Class A shareholders hold no vote on the two items subject to the revised mechanics, consistent with the company's constitutional documents.
- The amendment attaches Annex A establishing floor levels for annualized base salaries of specified Carvix executives, with annual bonuses calculated as a percentage of those salary figures.
Crown Reserve Acquisition Corp. I has revised the legal mechanics governing how shareholders will vote on its pending merger with Carvix, Inc. without altering anyone's actual voting rights. The change, executed August 26, 2026, updates the business combination agreement originally signed March 30, 2026, among Crown Reserve, its merger Subsidiary CRAC Merger Sub Inc. and Carvix.
Class A shareholders hold no vote on those two items, consistent with Article 49.2 of Crown Reserve's constitutional documents.
Executive Pay Terms Locked Into Annex A
Separately, the amendment attaches an Annex A setting floor levels for annualized base salaries owed to specified Carvix executives under future employment agreements. Annual Bonus opportunities for those executives will be calculated as a percentage of the Annex A salary figures. The amendment does not modify the Carvix disclosure schedule itself, and every other provision of the original agreement stays in force unless the amendment expressly overrides it.
Source(s)
- https://www.sec.gov/Archives/edgar/data/2070887/000121390026094001/ea0303505-8k425_crown1.htm
FAQs
Q: Does the amendment change how Crown Reserve shareholders vote on the Carvix deal?
A: No. The amendment does not change the voting rights of any securityholder; it only restates which proposals need a simple-majority ordinary resolution versus a two-thirds special resolution from Class B shares.
Q: What does the Annex A salary provision mean for the Carvix merger closing?
A: Annex A sets minimum annualized base salaries for certain Carvix executives, and employment agreements meeting those floors will satisfy a specific closing condition tied to the Carvix disclosure schedule under the merger agreement.
Q: What was changed in the merger agreement between Crown Reserve and Carvix?
A: The legal mechanics governing shareholder voting were revised on August 26, 2026, to update the original agreement signed March 30, 2026. However, this change did not alter any shareholder's actual voting rights or other substantive agreement terms.
Q: Do Class A shareholders have voting rights on all merger matters?
A: No. Class A shareholders hold no vote on the two specific items addressed by the revised mechanics, which is consistent with Article 49.2 of Crown Reserve's constitutional documents.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.